Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Advanced Solid Tumors × dalotuzumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Colorectal Neoplasms 3 Breast Neoplasms 3 Neoplasms 2 Rectal Neoplasms 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Neuroendocrine Tumors 1 Multiple Myeloma 1 Fallopian Tube Neoplasms 1 Advanced Solid Tumors 1

Interventions

tislelizumab 4 talazoparib 4 Docetaxel 4 PM 01183 2 Nivolumab 2 MLN 8237 2 Itraconazole 2 Fluorouracil 2 Cisplatin 2 Carboplatin 2 zimberelimab 1 ulixertinib 1 trifluridine tipiracil drug combination 1 sitravatinib 1 sapanisertib 1 pexidartinib 1 pevonedistat 1 peposertib 1 pembrolizumab 1 niraparib 1 mogamulizumab 1 lenvatinib 1 ixabepilone 1 eribulin 1 dalotuzumab 1 avelumab 1 ascrinvacumab 1 TLC 388 1 Rifampin 1 Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00635778 2018-10-09

MK-0646-002

Merck Sharp & Dohme LLC

Phase 1 Completed

50 enrolled 32 charts

Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡